Antitumor Activity of Small-Molecule SYK Inhibitor R788 and Fludarabinin Mono- and Combined Therapy in a Human B-CLL Xenograft Model

被引：0
|
作者：
Schueler, Julia [1 ]
Buchner, Maike [2 ]
Fiebig, Heinz-Herbert [1 ]
Veelken, Hendrik [3 ]
Zirlik, Katja [2 ]
机构：
[1] Oncotest GmbH, Freiburg, Germany
[2] Univ Hosp Freiburg, Freiburg, Germany
[3] Univ Freiburg, Med Ctr, D-7800 Freiburg, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：939 / 939
页数：1
相关论文
共 6 条
  • [1] Antitumor Activity of small-molecule SYK inhibitor R788 in mono- and combined therapy with Fludarabine in a human patient-derived B-CLL xenograft model
    Schueler, J.
    Klingner, K.
    Buchner, M.
    Fiebig, H-H
    Veelken, H.
    Zirlik, K.
    ONKOLOGIE, 2010, 33 : 184 - 185
  • [2] A new small-molecule Aurora B inhibitor shows antitumor activity in human cancer cell lines
    Yuanyuan Wu
    Jie Li
    Chenxiao Jiang
    Xianmei Yang
    Lihuan Cao
    Long Yu
    Molecular Biology Reports, 2015, 42 : 517 - 524
  • [3] A new small-molecule Aurora B inhibitor shows antitumor activity in human cancer cell lines
    Wu, Yuanyuan
    Li, Jie
    Jiang, Chenxiao
    Yang, Xianmei
    Cao, Lihuan
    Yu, Long
    MOLECULAR BIOLOGY REPORTS, 2015, 42 (02) : 517 - 524
  • [4] The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
    Suljagic, Mirza
    Longo, Pablo G.
    Bennardo, Sara
    Perlas, Emerald
    Leone, Giuseppe
    Laurenti, Luca
    Efremov, Dimitar G.
    BLOOD, 2010, 116 (23) : 4894 - 4905
  • [5] DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model
    Jimbo, T.
    Taira, T.
    Komatsu, T.
    Kumazawa, K.
    Maeda, N.
    Haginoya, N.
    Suzuki, T.
    Ota, M.
    Totoki, Y.
    Wada, C.
    Inaki, K.
    Isoyama, T.
    Uno, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
    Raben, D
    Bianco, C
    Damiano, V
    Bianco, R
    Melisi, D
    Mignogna, C
    D'Armiento, FP
    Cionini, L
    Bianco, AR
    Tortora, G
    Ciardiello, F
    Bunn, P
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (08) : 977 - 983
1